Exane Derivatives’s ChemoCentryx, Inc. CCXI Stock Holding History

Exane Derivatives’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2.28K	Hold	92	–	–	﹤0.01%	427
2022 Q1	$2.31K	Hold	92	–	–	﹤0.01%	742
2021 Q4	$3.35K	Sell	92 -18,314	-100%	-$643K	﹤0.01%	636
2021 Q3	$315K	Sell	18,406 -538	-3%	-$8.38K	0.08%	278
2021 Q2	$309K	Sell	18,944 -2,061	-10%	-$50.8K	0.07%	282
2021 Q1	$1.08M	Buy	21,005 +991	+5%	+$59.6K	0.31%	76
2020 Q4	$1.24M	Buy	20,014 +18,220	+1,016%	+$1.04M	0.36%	57
2020 Q3	$98.3K	Buy	1,794 +182	+11%	+$9.8K	0.03%	300
2020 Q2	$92.7K	Sell	1,612 -517	-24%	-$28.1K	0.02%	305
2020 Q1	$85.5K	Buy	+2,129	New	+$90.4K	0.02%	301

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Exane Derivatives's CCXI Position: Q2 2022 in Review

Exane Derivatives held its ChemoCentryx, Inc. (CCXI) position steady in Q2 2022 at 92 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #427.

Exane Derivatives first reported a position in CCXI in Q1 2020 and has held it in 10 quarters since. The position peaked at $1.24M in Q4 2020. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

Exane Derivatives held 92 shares of ChemoCentryx, Inc. worth $2.28K as of Q2 2022.
Exane Derivatives left its ChemoCentryx, Inc. share count unchanged in Q2 2022.
ChemoCentryx, Inc. made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #427 holding.
Exane Derivatives first reported a position in ChemoCentryx, Inc. in Q1 2020 and has held it in 10 quarters since.
Exane Derivatives's ChemoCentryx, Inc. position peaked at $1.24M in Q4 2020.
182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.